Stock Events

Stock Events

DBV Technologies 

$15.53
119
-$0.75-4.61% Thursday 20:00

Statistics

Day High
16.74
Day Low
15.4
52W High
26.19
52W Low
8.5
Volume
320,300
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29JulExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.44
-0.3
-0.16
-0.02
Expected EPS
-0.02118410896
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-228.25MNet Income

Analyst Ratings

53.00Average Price Target
The highest estimate is 55.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DBVT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap64.18B
Regeneron Pharmaceuticals, involved in developing treatments for allergies and inflammatory diseases, competing in the broader allergy treatment market.
Sanofi
SNY
Mkt Cap105.92B
Sanofi, a large pharmaceutical company with a focus on immunology and allergy treatments, including collaborations on therapies that could compete with DBV's offerings.
Novavax
NVAX
Mkt Cap1.46B
Novavax, works on vaccines that could potentially address allergies, indirectly competing by targeting the underlying causes of allergic reactions.
Moderna
MRNA
Mkt Cap19.8B
Moderna, known for mRNA technology, which could be applied to develop vaccines or treatments for allergies, potentially competing with DBV's approach.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.81B
BioMarin Pharmaceutical, focuses on rare diseases but has interests in developing treatments that could overlap with allergy and immunotherapy markets.
Adma Biologics
ADMA
Mkt Cap1.9B
ADMA Biologics, specializes in immune globulin products which could be used in treating allergies, offering an alternative to DBV's therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.92B
Vertex Pharmaceuticals, while primarily focused on cystic fibrosis, its research into other areas of medicine could lead to competitive treatments in the allergy space.
GSK
GSK
Mkt Cap106.31B
GlaxoSmithKline, a large pharmaceutical company with a diverse portfolio, including respiratory and allergy treatments, potentially competing across several areas of DBV's interest.

About

DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
Show more...
CEO
Mr. Daniel Tassé
Employees
106
Country
United States
ISIN
US23306J3095

Listings

F
DE
DBV1.F
STU
DE
DBV1.STU
STU
DE
DBV.STU
XETRA
DE
DBV.XETRA

0 Comments

Share your thoughts

FAQ

What is DBV Technologies stock price today?▼
The current price of DBVT is $15.53 USD — it has decreased by -4.61% in the past 24 hours. Watch DBV Technologies stock price performance more closely on the chart.
What is DBV Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange DBV Technologies stocks are traded under the ticker DBVT.
Is DBV Technologies stock price growing?▼
DBVT stock has fallen by -10.82% compared to the previous week, the month change is a -16.1% fall, over the last year DBV Technologies has showed a +57.66% increase.
When is the next DBV Technologies earnings date?▼
DBV Technologies is going to release the next earnings report on July 29, 2026.
What were DBV Technologies earnings last quarter?▼
DBVT earnings for the last quarter are -0.02 USD per share, whereas the estimation was -0.03 USD resulting in a +19.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is DBV Technologies revenue for the last year?▼
DBV Technologies revenue for the last year amounts to 0 USD.
What is DBV Technologies net income for the last year?▼
DBVT net income for the last year is -228.25M USD.
How many employees does DBV Technologies have?▼
As of June 19, 2026, the company has 106 employees.
In which sector is DBV Technologies located?▼
DBV Technologies operates in the Health & Wellness sector.
When did DBV Technologies complete a stock split?▼
The last stock split for DBV Technologies was on November 29, 2024 with a ratio of 1:5.
Where is DBV Technologies headquartered?▼
DBV Technologies is headquartered in Châtillon, United States.